Zhou Y P, Yang M, Yao P T, Ge Y B, Tang W, Wen Y, Lyu Z Y, Tan F W, Sun X, Li F, Li J, Li N
Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Comprehensive Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2020 Dec 23;42(12):1025-1033. doi: 10.3760/cma.j.cn112152-20190508-00293.
To understand the current status of clinical guidelines and consensus for lung cancer chemotherapy, evaluate and analyze the quality of lung cancer chemotherapy treatment guidelines, and provide references for the revision and improvement of lung cancer chemotherapy clinical decision-making and guidelines. Search Pubmed, EMbase, Cochrane Library (Cochrane Library), China Knowledge Network, Wanfang Database, China Biomedical Literature Database and other related databases and clinical practice guidelines related to lung cancer chemotherapy, and screen the literatures according to the established inclusion exclusion criteria. Use the appraisal of guidelines for research and evaluation Ⅱ (AGREE Ⅱ) and reporting items for practice guidelines in healthcare (RIGHT) tools to compare and evaluate the quality of the included guides and the level of reporting specifications. A total of 14 guidelines were included. The assessment results of AGREE Ⅱ showed that the average score of scope and purpose was 94 points, the average score of stakeholder involvement was 60 points, the average score of rigour of development was 43 points, the average score of clarity of presentation was 88 points, the average score of applicability was 50 points, the average score of editorial independence was 61 points. Seven guidelines were evaluated as A level, 6 guidelines were evaluated as B level, 1 guideline was evaluated as C level. The assessment results of RIGHT showed that, in addition to the basic information, the included guidelines have many deficiencies in 6 areas including background, evidence, recommendation, review and quality assurance, funding, declaration and management of interests and other information, and the normative gap between domestic and foreign guides was large. The overall quality of clinical guidelines for lung cancer chemotherapy is high, but the standardization needs to be strengthened. There is a big gap between the quality and standardization of domestic and foreign guides. Further developments of high-quality clinical practice guidelines and guidelines consistent with our country's actual situation are needed.
了解肺癌化疗临床指南与共识的现状,评估与分析肺癌化疗治疗指南质量,为肺癌化疗临床决策及指南的修订与完善提供参考。检索Pubmed、EMbase、Cochrane图书馆(Cochrane Library)、中国知网、万方数据库、中国生物医学文献数据库等相关数据库及与肺癌化疗相关的临床实践指南,并根据既定的纳入排除标准筛选文献。运用指南研究与评价Ⅱ(AGREE Ⅱ)及医疗保健实践指南报告条目(RIGHT)工具,对纳入指南的质量及报告规范水平进行比较与评价。共纳入14部指南。AGREE Ⅱ评估结果显示,范围与目的平均得分94分,利益相关者参与平均得分60分,制定严谨性平均得分43分,呈现清晰度平均得分88分,适用性平均得分50分,编辑独立性平均得分61分。7部指南评为A级,6部指南评为B级,1部指南评为C级。RIGHT评估结果显示,纳入指南除基本信息外,在背景、证据、推荐意见、评审与质量保证、资金、利益声明与管理等6个方面存在诸多不足,国内外指南规范性差距较大。肺癌化疗临床指南整体质量较高,但标准化仍需加强。国内外指南在质量与标准化方面存在较大差距。需要进一步制定高质量的临床实践指南以及符合我国实际情况的指南。